Search
Stories, the companies and people Loro tracks, and the primary records behind them — filings, donations, contracts and disclosures.
Company or person12
PFIZER INC
Company
PTC INC.
Company
Seer, Inc.
Company
PAID INC
Company
PLDT Inc.
Company
Net Power Inc.
Company
Polar Power, Inc.
Company
PLUG POWER INC
Company
iPower Inc.
Company
Pluri Inc.
Company
OppFi Inc.
Company
Ideal Power Inc.
Company
Primary record18
Medicus Pharma Ltd. filed 8-K
Item 7.01 Regulation FD Disclosure. On November 4, 2026, Medicus Pharma Ltd. (the "Company" or "Medicus") issued a press release announcing a non-binding letter of intent in connection with a potential business combinati
PFIZER INC filed 8-K
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On November 3, 2026, Pfizer Inc. (the “Company”) announced that
PFIZER INC filed 8-K
Item 2.02 Results of Operations and Financial Condition On November 3, 2026, Pfizer Inc. (“Pfizer”) issued a press release announcing its financial results for the third quarter of 2026. A copy of the press release is fu
Xeris Biopharma Holdings, Inc. filed 8-K
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Appointment of Director Menassie Taddese Effective as of Novemb
ENANTA PHARMACEUTICALS INC filed 8-K
Item 8.01 Other Events. As previously disclosed, Enanta Pharmaceuticals, Inc. (the “Company”) filed a patent infringement action in the Unified Patent Court (the “UPC”) of the European Union against Pfizer Inc. and certa
ManpowerGroup Inc. filed 8-K
Item 5.02 Election of Directors. On October 26, 2026, ManpowerGroup Inc. (the “Company”) appointed Lidia Fonseca to its Board of Directors, with service to begin on November 1, 2026. The size of the Company’s Board of Di
Arcutis Biotherapeutics, Inc. filed 8-K
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 23, 2026, the Board of Directors (the “Board”) of Ar
Faeth Therapeutics, Inc. filed 8-K
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 23, 2026, the Board of Directors (the “Board”) of F
Eloxx Pharmaceuticals, Inc. filed 8-K
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 19, 2026, the Board of Directors (the “Board”) of E
PFIZER INC filed SCHEDULE 13G
pursuant to Rule 424(b) under the Securities Act of 1933, as amended, on October 8, 2026. PFIZER VENTURES (US) LLC (82-5524518) DE 0.00 1265066.00 0.00 1265066.00 1265066.00 N 4.6 OO Percent of class outstanding represen
LISATA THERAPEUTICS, INC. filed 8-K
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (d) On October 13, 2026, upon the recommendation of the Nominat
PFIZER INC filed 4
SEC form 4 filed by PFIZER INC (CIK 78003) on 2026-09-29.
Unicycive Therapeutics, Inc. filed 8-K
Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers . On September 28, 2026, Unicycive Therapeutics, Inc. (the Company ) appointed Meredith S. Manning as an in
Larimar Therapeutics, Inc. filed 8-K
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. The Board of Directors (the Board ) of Larimar Therapeutics, In
PFIZER INC filed 4
SEC form 4 filed by PFIZER INC (CIK 78003) on 2026-09-29.
PFIZER INC filed 4
SEC form 4 filed by PFIZER INC (CIK 78003) on 2026-09-29.
Valion Bio, Inc. filed 8-K
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Appointment of Dean Zikria as Interim Chief Executive Officer O
Medicus Pharma Ltd. filed 8-K
Item 1.01. Entry into a Material Definitive Agreement. On September 2, 2026, Medicus Pharma Ltd. (the "Company"), through its wholly owned subsidiary, Medicus Pharma Inc., entered into a Co-Development and License Agreem